HomeCompareMEDOF vs NNN

MEDOF vs NNN: Dividend Comparison 2026

MEDOF yields 4.00% · NNN yields 5.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MEDOF wins by $457.00 in total portfolio value
10 years
MEDOF
MEDOF
● Live price
4.00%
Share price
$50.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.9K
Annual income
$517.11
Full MEDOF calculator →
NNN
NNN REIT Inc.
● Live price
5.66%
Share price
$42.03
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.5K
Annual income
$2,622.67
Full NNN calculator →

Portfolio growth — MEDOF vs NNN

📍 MEDOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMEDOFNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MEDOF + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MEDOF pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MEDOF
Annual income on $10K today (after 15% tax)
$340.00/yr
After 10yr DRIP, annual income (after tax)
$439.54/yr
NNN
Annual income on $10K today (after 15% tax)
$481.32/yr
After 10yr DRIP, annual income (after tax)
$2,229.27/yr
At 15% tax rate, NNN beats the other by $1,789.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MEDOF + NNN for your $10,000?

MEDOF: 50%NNN: 50%
100% NNN50/50100% MEDOF
Portfolio after 10yr
$25.7K
Annual income
$1,569.90/yr
Blended yield
6.10%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

MEDOF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
4.2
Piotroski
5/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+6.9% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MEDOF buys
0
NNN buys
2
PoliticianChamberTickerTypeAmountDate
Lisa McClain🏢 House$NNN▼ Sell$1,001 - $15,0002025-08-13
Lisa McClain🏢 House$NNN▲ Buy$1,001 - $15,0002025-06-17
Zoe Lofgren🏢 House$NNN▼ Sell$1,001 - $15,0002023-05-25
Ro Khanna🏢 House$NNN▼ Sell$1,001 - $15,0002022-01-20
Zoe Lofgren🏢 House$NNN▲ Buy$1,001 - $15,0002021-09-30
Zoe Lofgren🏢 House$NNN▼ Sell$1,001 - $15,0002020-03-23
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMEDOFNNN
Forward yield4.00%5.66%
Annual dividend / share$2.00$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6%
Portfolio after 10y$25.9K$25.5K
Annual income after 10y$517.11$2,622.67
Total dividends collected$4.6K$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: MEDOF vs NNN ($10,000, DRIP)

YearMEDOF PortfolioMEDOF Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$11,100$400.00$10,735$614.96+$365.00MEDOF
2$12,292$414.95$11,572$708.43+$720.00MEDOF
3$13,582$429.45$12,531$819.53+$1.1KMEDOF
4$14,976$443.47$13,633$952.29+$1.3KMEDOF
5$16,481$457.01$14,909$1,111.84+$1.6KMEDOF
6$18,105$470.04$16,392$1,304.77+$1.7KMEDOF
7$19,855$482.57$18,129$1,539.52+$1.7KMEDOF
8$21,739$494.59$20,173$1,827.08+$1.6KMEDOF
9$23,767$506.10$22,597$2,181.81+$1.2KMEDOF
10$25,948$517.11$25,491$2,622.67+$457.00MEDOF

MEDOF vs NNN: Complete Analysis 2026

MEDOFStock

Medios AG, together with its subsidiaries, engages in the wholesale of specialty pharmaceutical drugs in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies; and patient-specific therapies for dispensing individually dosed tablets. The company was founded in 2016 and is based in Berlin, Germany.

Full MEDOF Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this MEDOF vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MEDOF vs SCHDMEDOF vs JEPIMEDOF vs OMEDOF vs KOMEDOF vs MAINMEDOF vs ADCMEDOF vs EPRTMEDOF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.